New treatments outperforming placebo becoming less common

June 14, 2013
New treatments outperforming placebo becoming less common
The efficacy of new medical treatments compared with placebo has sharply declined over the last few decades, suggesting that comparative effectiveness studies are needed, according to a study published in the June issue of Health Affairs.

(HealthDay)—The efficacy of new medical treatments compared with placebo has sharply declined over the last few decades, suggesting that comparative effectiveness studies are needed, according to a study published in the June issue of Health Affairs.

Mark Olfson, M.D., M.P.H., from Columbia University in New York City, and Steven C. Marcus, Ph.D., from the University of Pennsylvania in Philadelphia, randomly selected and analyzed 315 placebo-controlled trials published in BMJ, the Journal of the American Medical Association, The Lancet, and the New England Journal of Medicine from 1966 to 2010.

The researchers found that the average effect size or average difference in efficacy fell significantly between the active treatment and placebo, from a peak odds ratio of 4.51 (1971 to 1980) to 1.36 (2001 to 2010).

"A decline in effect sizes in conventional placebo-controlled trials supports an increased emphasis on other avenues of research, including comparative studies on the safety, tolerability, and cost of treatments with established efficacy," Olfson and colleagues conclude.

Explore further: Imeglimin beneficial as add-on to metformin in T2DM

More information: Abstract
Full Text (subscription or payment may be required)

Related Stories

Imeglimin beneficial as add-on to metformin in T2DM

December 14, 2012

(HealthDay)—For patients with type 2 diabetes inadequately controlled by metformin alone, addition of the new oral anti-diabetes agent imeglimin improves glycemic control with good tolerability and safety, according to ...

Placebo often effective for treating headache in children

January 29, 2013

(HealthDay)—Placebo is often effective in treating children with headaches, and innovative strategies are needed to reduce the placebo response rate and prove drug effects in trials, according to two studies published online ...

Collagenase clostridium histolyticum OK in Peyronie's

April 26, 2013

(HealthDay)—For patients with Peyronie's disease, treatment with collagenase clostridium histolyticum (CCH) intralesional injections is efficacious and tolerable, according to research published online Feb. 1 in The Journal ...

Recommended for you

Can nicotine protect the aging brain?

September 20, 2016

Everyone knows that tobacco products are bad for your health, and even the new e-cigarettes may have harmful toxins. However, according to research at Texas A&M, it turns out the nicotine itself—when given independently ...

Science can shape healthy city planning

September 23, 2016

Previous studies have shown a correlation between the design of cities and growing epidemics of injuries and non-communicable diseases such as heart disease, diabetes and cancer. A three-part series published in The Lancet ...

50-country comparison of child and youth fitness levels

September 21, 2016

An international research team co-led from the Children's Hospital of Eastern Ontario (CHEO) and the University of North Dakota studied the aerobic fitness levels of children and youth across 50 countries. The results are ...

2 comments

Adjust slider to filter visible comments by rank

Display comments: newest first

JRi
5 / 5 (1) Jun 15, 2013
Probably something to do with more strict guidelines, how tests need to be carried out nowadays. Laws require to inform authorities in advance when starting new tests. More difficult for pharmaceutical companies to "forget" the trials that failed to give positive outcome.
Wolf358
5 / 5 (1) Jun 15, 2013
Maybe it's all of the new improved extra-strength placebos....

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.